Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

2.

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis.

Edo Solsona MD, Monte Boquet E, Casanova Estruch B, Poveda Andrés JL.

Patient Prefer Adherence. 2017 Mar 2;11:415-421. doi: 10.2147/PPA.S127508.

3.

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.

Munsell M, Frean M, Menzin J, Phillips AL.

Patient Prefer Adherence. 2016 Dec 30;11:55-62. doi: 10.2147/PPA.S118107.

4.

Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.

Jernas Ł, Wencel J, Wiak A, Bieniek M, Bartosik-Psujek H.

PLoS One. 2016 Oct 3;11(10):e0157950. doi: 10.1371/journal.pone.0157950.

5.

Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided Quality.

Di Battista G, Bertolotto A, Gasperini C, Ghezzi A, Maimone D, Solaro C.

Mult Scler Int. 2014;2014:752318. doi: 10.1155/2014/752318.

6.

An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy.

Aylward BS, Rausch JR, Modi AC.

J Pediatr Psychol. 2015 Jan-Feb;40(1):66-74. doi: 10.1093/jpepsy/jsu010.

7.

Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.

Fox RJ, Salter AR, Tyry T, Sun J, You X, Laforet G, Campagnolo D.

Int J MS Care. 2013 Winter;15(4):194-201. doi: 10.7224/1537-2073.2012-034.

8.
9.

Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.

Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Limmroth V; Study Group..

BMC Neurol. 2013 Sep 6;13:117. doi: 10.1186/1471-2377-13-117.

10.

Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain.

Fernández O, Agüera E, Izquierdo G, Millán-Pascual J, Ramió I Torrentà L, Oliva P, Argente J, Berdei Y, Soler JM, Carmona O, Errea JM, Farrés J; Group on Adherence to IFNb-1b in Spain..

PLoS One. 2012;7(5):e35600. doi: 10.1371/journal.pone.0035600. Erratum in: PLoS One. 2012;7(6). doi:10.1371/annotation/35c70f05-8483-4310-aa2a-4665f4842129. Agüera, Javier [corrected Agüera, Eduardo]; Millán-Pascual, Javier [corrected to Millán-Pascual, Jorge]Argente, Javier [correced to Argente, Joaquin].

11.

Patient perceptions of multiple sclerosis and its treatment.

de Seze J, Borgel F, Brudon F.

Patient Prefer Adherence. 2012;6:263-73. doi: 10.2147/PPA.S27038.

12.

Improving patient-physician dialog: commentary on the results of the MS Choices survey.

Lugaresi A, Ziemssen T, Oreja-Guevara C, Thomas D, Verdun E.

Patient Prefer Adherence. 2012;6:143-52. doi: 10.2147/PPA.S27932.

13.

The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis.

Riñon A, Buch M, Holley D, Verdun E.

Patient Prefer Adherence. 2011;5:629-43. doi: 10.2147/PPA.S26479.

14.

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.

BMC Neurol. 2011 Mar 30;11:40. doi: 10.1186/1471-2377-11-40.

15.

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.

Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M.

Patient Prefer Adherence. 2011 Jan 20;5:73-84. doi: 10.2147/PPA.S15702.

16.

Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).

Wicks P, Massagli M, Kulkarni A, Dastani H.

J Med Internet Res. 2011 Jan 24;13(1):e12. doi: 10.2196/jmir.1687.

Supplemental Content

Support Center